SCHEMBL4358786

SCHEMBL4358786

CC(=O)Nc1nc(N)c2cc(-c3ccc(F)cc3)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 3/20 0.52
PIK3CA P42336 1/20 0.47
NPY1R P25929 1/20 0.44
NPY5R Q15761 1/20 0.44
ADORA3 P0DMS8 3/20 0.44
ADORA2A P29274 1/20 0.44
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
ADORA1 P30542 1/20 0.43
RAD52 P43351 1/20 0.42
PIK3CG P48736 2/20 0.41
RAB9A P51151 1/20 0.41
PDPK1 O15530 1/20 0.41
DYRK1A Q13627 1/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
DHODH Q02127 1/20 0.41
EGLN1 Q9GZT9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359201 0.88 MAP4K4 (0.53) MAP4K4PIK3CANPY1RNPY5RADORA3
SCHEMBL4360417 0.87 MAP4K4 (0.46) MAP4K4PIK3CANPY1RNPY5RADORA3
SCHEMBL3333818 0.86 ADORA3 (0.45) MAP4K4PIK3CAADORA3ADORA2AADORA1
SCHEMBL4351087 0.85 TRIM58 (0.44) MAP4K4PIK3CAADORA3ADORA2AADORA1
SCHEMBL4358497 0.84 TRIM58 (0.58) MAP4K4PIK3CAADORA3ADORA2AADORA1
SCHEMBL4362226 0.82 ADORA3 (0.45) MAP4K4PIK3CAADORA3ADORA2ATP53
SCHEMBL3340764 0.82 CYP1A2 (0.43) MAP4K4PIK3CAADORA3ADORA2AMAPT
SCHEMBL4355749 0.81 PIK3CA (0.53) MAP4K4PIK3CAADORA3TP53MAPT
SCHEMBL4362758 0.80 EGLN1 (0.48) PIK3CATP53MAPTRAD52EGLN1
SCHEMBL3335675 0.80 MAPT (0.41) MAP4K4PIK3CAADORA3ADORA2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US claimed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US claimed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 MAP4K4 1801/4885PIK3CA 3986/4885NPY1R 435/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 MAP4K4 1801/4885PIK3CA 3986/4885NPY1R 435/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 MAP4K4 1921/4885PIK3CA 4078/4885NPY1R 408/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 MAP4K4 1837/4885PIK3CA 3799/4885NPY1R 380/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 MAP4K4 1837/4885PIK3CA 3799/4885NPY1R 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.